S&P 500   4,535.26 (+0.35%)
DOW   35,603.58 (+0.41%)
QQQ   375.05 (-0.11%)
AAPL   148.98 (+0.15%)
MSFT   307.70 (-0.17%)
FB   341.02 (+0.30%)
GOOGL   2,840.17 (-0.86%)
TSLA   865.74 (+0.17%)
AMZN   3,423.75 (-0.59%)
NVDA   220.69 (-0.99%)
BABA   177.31 (+0.18%)
NIO   39.68 (-0.87%)
CGC   14.24 (-0.70%)
GE   105.47 (+0.71%)
AMD   116.42 (+0.08%)
MU   68.50 (+1.38%)
T   25.97 (+1.48%)
F   15.95 (+3.44%)
ACB   7.59 (+1.88%)
DIS   170.66 (-0.30%)
PFE   42.85 (+1.81%)
BA   216.59 (+0.29%)
AMC   41.00 (+0.49%)
S&P 500   4,535.26 (+0.35%)
DOW   35,603.58 (+0.41%)
QQQ   375.05 (-0.11%)
AAPL   148.98 (+0.15%)
MSFT   307.70 (-0.17%)
FB   341.02 (+0.30%)
GOOGL   2,840.17 (-0.86%)
TSLA   865.74 (+0.17%)
AMZN   3,423.75 (-0.59%)
NVDA   220.69 (-0.99%)
BABA   177.31 (+0.18%)
NIO   39.68 (-0.87%)
CGC   14.24 (-0.70%)
GE   105.47 (+0.71%)
AMD   116.42 (+0.08%)
MU   68.50 (+1.38%)
T   25.97 (+1.48%)
F   15.95 (+3.44%)
ACB   7.59 (+1.88%)
DIS   170.66 (-0.30%)
PFE   42.85 (+1.81%)
BA   216.59 (+0.29%)
AMC   41.00 (+0.49%)
S&P 500   4,535.26 (+0.35%)
DOW   35,603.58 (+0.41%)
QQQ   375.05 (-0.11%)
AAPL   148.98 (+0.15%)
MSFT   307.70 (-0.17%)
FB   341.02 (+0.30%)
GOOGL   2,840.17 (-0.86%)
TSLA   865.74 (+0.17%)
AMZN   3,423.75 (-0.59%)
NVDA   220.69 (-0.99%)
BABA   177.31 (+0.18%)
NIO   39.68 (-0.87%)
CGC   14.24 (-0.70%)
GE   105.47 (+0.71%)
AMD   116.42 (+0.08%)
MU   68.50 (+1.38%)
T   25.97 (+1.48%)
F   15.95 (+3.44%)
ACB   7.59 (+1.88%)
DIS   170.66 (-0.30%)
PFE   42.85 (+1.81%)
BA   216.59 (+0.29%)
AMC   41.00 (+0.49%)
S&P 500   4,535.26 (+0.35%)
DOW   35,603.58 (+0.41%)
QQQ   375.05 (-0.11%)
AAPL   148.98 (+0.15%)
MSFT   307.70 (-0.17%)
FB   341.02 (+0.30%)
GOOGL   2,840.17 (-0.86%)
TSLA   865.74 (+0.17%)
AMZN   3,423.75 (-0.59%)
NVDA   220.69 (-0.99%)
BABA   177.31 (+0.18%)
NIO   39.68 (-0.87%)
CGC   14.24 (-0.70%)
GE   105.47 (+0.71%)
AMD   116.42 (+0.08%)
MU   68.50 (+1.38%)
T   25.97 (+1.48%)
F   15.95 (+3.44%)
ACB   7.59 (+1.88%)
DIS   170.66 (-0.30%)
PFE   42.85 (+1.81%)
BA   216.59 (+0.29%)
AMC   41.00 (+0.49%)
OTCMKTS:BTHE

Boston Therapeutics Stock Forecast, Price & News

$0.02
+0.01 (+45.83 %)
(As of 10/19/2021 03:59 PM ET)
Add
Compare
Today's Range
$0.01
$0.02
50-Day Range
$0.01
$0.02
52-Week Range
$0.01
$0.07
Volume88,386 shs
Average Volume133,524 shs
Market Capitalization$1.94 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.62
30 days | 90 days | 365 days | Advanced Chart
Receive BTHE News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Boston Therapeutics logo

About Boston Therapeutics

Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BTHE
Employees
2
Year Founded
N/A

Sales & Book Value

Annual Sales
$10,000.00
Book Value
($0.08) per share

Profitability

Net Income
$-910,000.00
Net Margins
-10,088.89%
Return on Assets
-19,911.75%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$1.94 million
Next Earnings Date
12/16/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.07 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












Boston Therapeutics (OTCMKTS:BTHE) Frequently Asked Questions

What stocks does MarketBeat like better than Boston Therapeutics?

Wall Street analysts have given Boston Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Boston Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Boston Therapeutics' next earnings date?

Boston Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, December 16th 2021.
View our earnings forecast for Boston Therapeutics
.

How were Boston Therapeutics' earnings last quarter?

Boston Therapeutics, Inc. (OTCMKTS:BTHE) announced its quarterly earnings results on Monday, May, 14th. The company reported ($0.03) earnings per share (EPS) for the quarter. The company earned $0.01 million during the quarter.
View Boston Therapeutics' earnings history
.

How has Boston Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Boston Therapeutics' stock was trading at $0.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BTHE stock has increased by 75.0% and is now trading at $0.0175.
View which stocks have been most impacted by COVID-19
.

Who are Boston Therapeutics' key executives?

Boston Therapeutics' management team includes the following people:
  • David Gerald Ludvigson, Chief Executive Officer, CFO, Secretary & Director

What other stocks do shareholders of Boston Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Therapeutics investors own include Dynavax Technologies (DVAX), NeXt Innovation (GSVC), InterCloud Systems (ICLD), Inpixon (INPX), PositiveID (PSID), Firsthand Technology Value Fund (SVVC), ARCA biopharma (ABIO), Acorn Energy (ACFN), Apollo Investment (AINV) and Ambarella (AMBA).

What is Boston Therapeutics' stock symbol?

Boston Therapeutics trades on the OTCMKTS under the ticker symbol "BTHE."

How do I buy shares of Boston Therapeutics?

Shares of BTHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Boston Therapeutics' stock price today?

One share of BTHE stock can currently be purchased for approximately $0.02.

How much money does Boston Therapeutics make?

Boston Therapeutics has a market capitalization of $1.94 million and generates $10,000.00 in revenue each year.

How many employees does Boston Therapeutics have?

Boston Therapeutics employs 2 workers across the globe.

What is Boston Therapeutics' official website?

The official website for Boston Therapeutics is www.bostonti.com.

Where are Boston Therapeutics' headquarters?

Boston Therapeutics is headquartered at 354 MERRIMACK STREET #4, LAWRENCE MA, 01843.

How can I contact Boston Therapeutics?

Boston Therapeutics' mailing address is 354 MERRIMACK STREET #4, LAWRENCE MA, 01843. The company can be reached via phone at (603) 935-9799 or via email at [email protected].


This page was last updated on 10/20/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.